Literature DB >> 14720002

The role of DOTS in tuberculosis treatment and control.

Peter D O Davies1.   

Abstract

Directly Observed Therapy Shortcourse (DOTS) is composed of five distinct elements: political commitment; microscopy services; drug supplies; surveillance and monitoring systems and use of highly efficacious regimens; and direct observation of treatment. The difference in the way the term 'DOTS' as defined by WHO and interpreted by many observers has led to some misunderstanding. WHO generally uses the term to mean the five components of DOTS. But the word 'DOTS' is an acronym for Directly Observed Therapy Shortcourse. Many workers therefore interpret DOTS purely as direct supervision of therapy. DOTS is not an end in itself but a means to an end. In fact it has two purposes, to ensure that the patient with tuberculosis (TB) completes therapy to cure and to prevent drug resistance from developing in the community. The main criticism of DOTS rightly derives from the fact that some properly conducted randomized, controlled trials of directly observed therapy with or without the other components have shown no benefit from it. The problem is that it is impossible to design a study of modern directly observed therapy against the previous self-administered, poorly-resourced programs. As soon as a study is implemented, the attention to patients in the control (non-directly observed therapy) arm inevitably improves from the previous non-trial service situation. What is of concern is that in some trials less than 70% cure rates were achieved even in the direct observation arm. With no new drugs or adjuvant treatment available to bring the length of treatment down to substantially less than 6 months, DOTS offers the best means we have at our disposal for TB control.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14720002     DOI: 10.1007/bf03256649

Source DB:  PubMed          Journal:  Am J Respir Med        ISSN: 1175-6365


  15 in total

1.  More than ten years of DOTS in Bosnia and Herzegovina.

Authors:  Hasan Zutić; Zehra Dizdarević; Aida Ustamujić; Zlatan Hadzimurtezić
Journal:  Bosn J Basic Med Sci       Date:  2008-02       Impact factor: 3.363

2.  Use of eCompliance, an innovative biometric system for monitoring of tuberculosis treatment in rural Uganda.

Authors:  Sarah Jane Snidal; Genevieve Barnard; Emmanuel Atuhairwe; Yanis Ben Amor
Journal:  Am J Trop Med Hyg       Date:  2015-04-06       Impact factor: 2.345

3.  Tuberculosis in London: a decade and a half of no decline [corrected].

Authors:  Sarah R Anderson; Helen Maguire; Jacqui Carless
Journal:  Thorax       Date:  2006-11-13       Impact factor: 9.139

4.  Host-Mediated Bioactivation of Pyrazinamide: Implications for Efficacy, Resistance, and Therapeutic Alternatives.

Authors:  Laura E Via; Rada Savic; Danielle M Weiner; Matthew D Zimmerman; Brendan Prideaux; Scott M Irwin; Eddie Lyon; Paul O'Brien; Pooja Gopal; Seokyong Eum; Myungsun Lee; Jean-Philippe Lanoix; Noton K Dutta; TaeSun Shim; Jeong Su Cho; Wooshik Kim; Petros C Karakousis; Anne Lenaerts; Eric Nuermberger; Clifton E Barry; Véronique Dartois
Journal:  ACS Infect Dis       Date:  2015-05-08       Impact factor: 5.084

5.  Evaluating the efficacy of stool sample on Xpert MTB/RIF Ultra and its comparison with other sample types by meta-analysis for TB diagnostics.

Authors:  Vishal Sharma; Anoop Singh; Mohita Gaur; Deepti Rawat; Anjali Yadav; Chanchal Kumar; Mandira Varma-Basil; Sheelu Lohiya; Vishal Khanna; Ashwani Khanna; Anil Chaudhry; Yogendra Singh; Richa Misra
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-05-04       Impact factor: 3.267

6.  Characterization of the Mycobacterium tuberculosis 4-diphosphocytidyl-2-C-methyl-D-erythritol synthase: potential for drug development.

Authors:  Hyungjin Eoh; Amanda C Brown; Lori Buetow; William N Hunter; Tanya Parish; Devinder Kaur; Patrick J Brennan; Dean C Crick
Journal:  J Bacteriol       Date:  2007-10-05       Impact factor: 3.490

7.  Efficacy of directly observed treatment short-course intermittent regimen in spinal tuberculosis.

Authors:  Rejith Valsalan; Rajesh Purushothaman; Mk Raveendran; Balaji Zacharia; Sibin Surendran
Journal:  Indian J Orthop       Date:  2012-03       Impact factor: 1.251

8.  In silico-based high-throughput screen for discovery of novel combinations for tuberculosis treatment.

Authors:  Ragini Singh; Vasanthi Ramachandran; Radha Shandil; Sreevalli Sharma; Swati Khandelwal; Malancha Karmarkar; Naveen Kumar; Suresh Solapure; Ramanatha Saralaya; Robert Nanduri; Vijender Panduga; Jitendar Reddy; K R Prabhakar; Swaminathan Rajagopalan; Narasimha Rao; Shridhar Narayanan; Anand Anandkumar; V Balasubramanian; Santanu Datta
Journal:  Antimicrob Agents Chemother       Date:  2015-07-06       Impact factor: 5.191

9.  The identification of risk factors associated with patient and healthcare system delays in the treatment of tuberculosis in Tabriz, Iran.

Authors:  Mohammad Ebrahimi Kalan; Hassan Yekrang Sis; Vinaya Kelkar; Scott H Harrison; Gregory D Goins; Mohammad Asghari Jafarabadi; Jian Han
Journal:  BMC Public Health       Date:  2018-01-24       Impact factor: 3.295

10.  Evaluation of the Directly Observed Treatment's Acceptance by Tuberculosis Patients in the Republic of Macedonia.

Authors:  Biljana Ilievska-Poposka; Maja Zakoska; Vladimir Mitreski
Journal:  Open Access Maced J Med Sci       Date:  2018-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.